Surapaneni KRIHNA MOHAN, Vishnu Priya VEERARAGHAVAN, Mallika JAUNU

Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH)

Background/aim: Vascular endothelial growth factor (VEGF) is associated with various ischemic and inflammatory diseases, and plays an important role in the development of liver fibrosis and hepatocarcinogenesis in nonalcoholic steatohepatitis (NASH). In this study, the comparative effect of pioglitazone, quercetin, and hydroxy citric acid on VEGF mRNA in experimentally induced NASH was investigated. Materials and methods: The experimental protocol consisted of five groups: control, NASH, NASH + pioglitazone, NASH + quercetin, and NASH + hydroxy citric acid. The VEGF mRNA expression was evaluated by reverse transcription polymerase chain reaction (RT-PCR) analysis for all experimental groups, and the levels of VEGF mRNA were quantitatively measured by densitometry. Results: A higher expression of VEGF mRNA was found in the hepatic cells of rats with experimentally induced NASH compared to the control group. A very mild increase in VEGF mRNA expression was observed in the rats treated with quercetin. In contrast, a mild increase in the expression of VEGF mRNA was observed in the rats treated with pioglitazone and hydroxy citric acid. Conclusion: Quercetin exhibited an effective inhibition of VEGF mRNA expression, while a lower inhibition of the VEGF mRNA level was observed in the hydroxy citric acid- and the pioglitazone-treated rats.

PDF

___

Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K et al. Leptin- mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983991.
Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012; 59: 442 449.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113121.
Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004; 2: 10481058.
Ahmed MH, Byrne CD. Non-alcoholic steatohepatitis. In Byrne CD, D Wild S, editors. Metabolic Syndrome. Chichester, UK: John Wiley & Sons; 2005. pp. 279305.
Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 2010; 19: 415423.
Surapaneni KM, Jainu M. Pioglitazone, quercetin, and hydroxy citric acid effect on hepatic biomarkers in non alcoholic steatohepatitis. Phcog Res 2014; 6: 153162.
Surapaneni KM, Jainu M. Effect of pioglitazone, quercetin, and hydroxy citric acid on the lipid profile and lipoproteins in experimentally induced non-alcoholic steatohepatitis (NASH). Indian J Pharm Educ Res 2014; 48: 3238.
9. Surapaneni KM, Jainu M. Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. J Phyiol Pharmacol 2014; 65: 6774.
10. Surapaneni KM, Saraswathi P, Jainu M. Non alcoholic steatohepatitis (NASH) experimental model induction in rats. Int J Pharm Bio Sci 2012; 3: 10851090.
11. Surapaneni KM, Sarswathi P, Jainu M. Role of pioglitazone, quercetin and hydroxy citric acid against non alcoholic steatohepatitis (NASH) - histological and scanning electron microscopy (SEM) studies in an experimental model of NASH. Asian J Pharm Clin Res, 2012; 5: 244247.
12. Biscetti F, Straface G, Arena V, Stigliano E, Pecorini G, Rizzo P, De Angelis G, Iuliano L, Ghirlanda G, Flex A. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation. Cardiovasc Diabetol 2009; 8: 49.
13. Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 23092317.
14. Jeon H, Kim H, Choi D, Kim D, Park SY, Kim YJ, Kim YM, Jung Y. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol 2007; 71: 16761684.